Ralliant (NYSE:RAL) Stock Rating Lowered by Wall Street Zen

Ralliant (NYSE:RAL) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Sunday.

A number of other equities analysts also recently issued reports on the company. Morgan Stanley lifted their price target on Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a research note on Tuesday, June 23rd. Oppenheimer increased their price objective on Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 13th. Truist Financial restated a “buy” rating and issued a $68.00 target price (up from $53.00) on shares of Ralliant in a report on Wednesday, May 13th. Evercore assumed coverage on Ralliant in a research report on Tuesday, June 9th. They set an “outperform” rating and a $80.00 target price on the stock. Finally, Vertical Research cut Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price objective on the stock. in a research note on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $73.00.

Ralliant Stock Performance

RAL opened at $69.75 on Friday. Ralliant has a 1-year low of $37.27 and a 1-year high of $75.41. The company has a market cap of $7.81 billion and a price-to-earnings ratio of -6.38. The company’s fifty day moving average price is $66.65 and its two-hundred day moving average price is $53.94. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73.

Ralliant (NYSE:RAL) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The firm had revenue of $534.60 million during the quarter. The company’s quarterly revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, analysts expect that Ralliant will post 2.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Ralliant

Several institutional investors have recently added to or reduced their stakes in RAL. Danske Bank A S bought a new stake in Ralliant in the fourth quarter worth about $25,000. Allworth Financial LP increased its stake in shares of Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after purchasing an additional 293 shares during the last quarter. V Square Quantitative Management LLC purchased a new stake in shares of Ralliant during the 4th quarter worth approximately $26,000. Palisade Asset Management LLC purchased a new stake in shares of Ralliant during the 3rd quarter worth approximately $26,000. Finally, Versant Capital Management Inc raised its holdings in shares of Ralliant by 230.1% in the 2nd quarter. Versant Capital Management Inc now owns 604 shares of the company’s stock worth $44,000 after purchasing an additional 421 shares during the period.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.